VanEck Associates
PLX icon

VanEck Associates’s Protalix BioTherapeutics PLX Stock Holding History

VanEck Associates’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,096
Closed -$35K – 1036
2020
Q3 		$35K Buy
9,096
+190
+2% +$687 ﹤0.01% 965
2020
Q2 		$34K Buy
+8,906
New +$30.4K ﹤0.01% 935
2019
Q2 		– Sell
-7,732
Closed -$34K – 850
2019
Q1 		$34K Buy
7,732
+180
+2% +$811 ﹤0.01% 805
2018
Q4 		$23K Buy
7,552
+1,963
+35% +$9.32K ﹤0.01% 781
2018
Q3 		$41K Buy
5,589
+320
+6% +$1.61K ﹤0.01% 764
2018
Q2 		$23K Buy
5,269
+1,532
+41% +$6.81K ﹤0.01% 835
2018
Q1 		$20K Buy
3,737
+249
+7% +$1.64K ﹤0.01% 718
2017
Q4 		$23K Sell
3,488
-671
-16% -$4.53K ﹤0.01% 711
2017
Q3 		$24K Buy
4,159
+185
+5% +$1.19K ﹤0.01% 721
2017
Q2 		$33K Buy
+3,974
New +$37.3K ﹤0.01% 727
2016
Q2 		– Sell
-10,682
Closed -$90K – 883
2016
Q1 		$90K Buy
10,682
+61
+0.6% +$523 ﹤0.01% 684
2015
Q4 		$108K Buy
10,621
+3,942
+59% +$40.1K ﹤0.01% 614
2015
Q3 		$79K Buy
6,679
+853
+15% +$13.6K ﹤0.01% 642
2015
Q2 		$114K Buy
+5,826
New +$121K ﹤0.01% 639
2013
Q4 		– Sell
-2,149
Closed -$97K – 692
2013
Q3 		$97K Buy
2,149
+1,141
+113% +$58.6K ﹤0.01% 604
2013
Q2 		$49K Buy
+1,008
New +$53.5K ﹤0.01% 626

Other funds holding PLX

BCM
Burrage Capital Management Boston, Massachusetts $99.7M AUM 66.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VanEck Associates's PLX Position: Q4 2020 in Review

VanEck Associates sold out of Protalix BioTherapeutics (PLX) in Q4 2020, closing a stake of 9,096 shares — an estimated $35K sold.

VanEck Associates first reported a position in PLX in Q2 2013 and held it in 16 quarters. The position peaked at $114K in Q2 2015. 23 funds tracked by Wall St. Rank hold PLX as of Q4 2020.

  • VanEck Associates reported no remaining Protalix BioTherapeutics position as of Q4 2020 after selling out during the quarter.
  • VanEck Associates sold 9,096 Protalix BioTherapeutics shares in Q4 2020, an estimated $35K.
  • VanEck Associates first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 16 quarters.
  • VanEck Associates's Protalix BioTherapeutics position peaked at $114K in Q2 2015.
  • 23 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2020.

Based on VanEck Associates's 13F filing for Q4 2020, filed 9 Feb 2021.